Factory Supply 4-Bromo-2-Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7

To fulfill the customers’ over-expected satisfaction , we have now our strong crew to provide our greatest general assistance which incorporates promoting, gross sales, planning, creation, top quality controlling, packing, warehousing and logistics for Factory Supply 4-Bromo-2-Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, We are sincere and open. We look forward to your visit and establishing trustworthy and long-term standing relationship.
To fulfill the customers’ over-expected satisfaction , we have now our strong crew to provide our greatest general assistance which incorporates promoting, gross sales, planning, creation, top quality controlling, packing, warehousing and logistics for China CAS 112704-79-7 and 112704-79-7, Our goods have won an excellent reputation at each of the related nations. Because the establishment of our firm. we’ve got insisted on our production procedure innovation together with the most recent modern day managing method, attracting a sizable quantity of talents within this industry. We regard the solution good quality as our most vital essence character.

1-Bromo-2-methoxy-3-nitro-benzene is used as the intermediate of Eltrombopag .
Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is also the first drug approved by the US FDA for the treatment of AA in recent 30 years.
In december2012, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC), so that hepatitis C patients with poor prognosis due to low platelet count can start and maintain interferon based standard therapy for liver diseases. On february3,2014, GlaxoSmithKline announced that the FDA granted the breakthrough treatment drug qualification of Eltrombopag for the treatment of hemopenia in patients with severe chemicalbook aplastic anemia (SAA) who did not fully respond to immunotherapy. On August 24, 2015, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in adults and children aged 1 year and over with chronic immune thrombocytopenia (ITP) who have insufficient response to corticosteroids, immunoglobulins or splenectomy. On january4,2018, Eltrombopag was approved to be listed in China for the treatment of primary immune thrombocytopenia (ITP).

To fulfill the customers’ over-expected satisfaction , we have now our strong crew to provide our greatest general assistance which incorporates promoting, gross sales, planning, creation, top quality controlling, packing, warehousing and logistics for Factory Supply 4-Bromo-2-Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, We are sincere and open. We look forward to your visit and establishing trustworthy and long-term standing relationship.
Factory Supply China CAS 112704-79-7 and 112704-79-7, Our goods have won an excellent reputation at each of the related nations. Because the establishment of our firm. we’ve got insisted on our production procedure innovation together with the most recent modern day managing method, attracting a sizable quantity of talents within this industry. We regard the solution good quality as our most vital essence character.